Keyword Analysis & Research: bevacizumab biosimilar

Keyword Analysis


Keyword CPC PCC Volume Score Length of keyword
bevacizumab biosimilar1.280.315889722
bevacizumab0.520.691916911
biosimilar0.970.134528810

Keyword Research: People who searched bevacizumab biosimilar also searched

Keyword CPC PCC Volume Score
bevacizumab biosimilar0.370.7851259

Search Results related to bevacizumab biosimilar on Search Engine

  • FDA approves first biosimilar for the treatment of cancer

    fda.gov

    https://www.fda.gov/news-events/press-announcements/fda-approves-first-biosimilar-treatment-cancer

    WEBSeptember 14, 2017. Statement From: The U.S. Food and Drug Administration today approved Mvasi (bevacizumab-awwb) as a biosimilar to Avastin (bevacizumab) for the treatment of multiple types of...

    DA: 27 PA: 73 MOZ Rank: 77

  • The 4 Biosimilar Drugs for Avastin (and What to Know About …

    goodrx.com

    https://www.goodrx.com/avastin/biosimilar-drug

    WEBJan 23, 2023 · Four biosimilar versions of Avastin are currently approved: Mvasi (bevacizumab-awwb), Zirabev (bevacizumab-bvzr), Alymsys (bevacizumab-maly), and Vegzelma (bevacizumab-adcd). Avastin’s biosimilars may help you save money on your treatment without sacrificing safety or effectiveness.

    DA: 63 PA: 60 MOZ Rank: 13

  • Avastin® (bevacizumab) Biosimilar | MVASI® (bevacizumab-awwb)

    mvasi.com

    https://www.mvasi.com/hcp

    WEBMVASI® IS THE ONLY BEVACIZUMAB BIOSIMILAR THAT PROVIDES THE AMGEN LEVEL OF SUPPORT TO YOUR PATIENTS AND PRACTICE. MVASI® is indicated for the treatment of: Metastatic colorectal cancer (mCRC) Non-squamous non-small cell lung cancer (NSCLC) Recurrent glioblastoma (rGBM) Metastatic renal cell carcinoma …

    DA: 12 PA: 51 MOZ Rank: 64

  • Efficacy and Safety of Bevacizumab Biosimilars Compared With …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9294356/

    WEBJul 5, 2022 · We systematically summarized the current evidence for the efficacy and safety of bevacizumab biosimilars in patients with advanced non-small cell lung cancer (NSCLC) or metastatic colorectal cancer (CRC).

    DA: 39 PA: 85 MOZ Rank: 66

  • Biosimilar Product Information | FDA

    fda.gov

    https://www.fda.gov/drugs/biosimilars/biosimilar-product-information

    WEBAug 24, 2023 · Press Release: FDA approves first biosimilar for the treatment of certain breast and stomach cancers: Mvasi (Bevacizumab-awwb) September 2017: Avastin (bevacizumab) Mvasi information

    DA: 8 PA: 3 MOZ Rank: 29

  • Comparison of efficacy and safety of bevacizumab biosimilar and

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9273685/

    WEBJan 10, 2022 · PMID: 35836506. Comparison of efficacy and safety of bevacizumab biosimilar and original bevacizumab in non-squamous non-small cell lung cancer: a systematic review and meta-analysis. Xian Xiao, # 1 , 2 , 3 , # Guixing Zhang, # 1 , 2 , 3 , # Binxu Sun, 1 , 2 Chaoran Wang, 1 , 2 , 3 Xiaoqun Wang, 1 , 2 Fanming Kong, 1 , 2 and …

    DA: 95 PA: 21 MOZ Rank: 32

  • Official Patient Website | ZIRABEV™ (bevacizumab-bvzr) | Safety …

    zirabev.com

    https://www.zirabev.com/

    WEBLearn About Biosimilars. Financial Support & Resources. What kinds of cancer can ZIRABEV help to treat? INDICATIONS. Metastatic Colorectal Cancer (mCRC) ZIRABEV is approved to treat mCRC for: First- or second-line treatment in combination with intravenous fluorouracil-based chemotherapy.

    DA: 81 PA: 60 MOZ Rank: 45

  • SB8: A Bevacizumab Biosimilar - PMC - National Center for …

    nih.gov

    https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7733936/

    WEBNov 18, 2020 · SB8 is a biosimilar of the monoclonal anti-vascular endothelial growth factor (VEGF) antibody bevacizumab. The product details are summarized in Table. 1. SB8 is approved in the EU for same types of cancer as bevacizumab (Table. 2) [ 1 ].

    DA: 5 PA: 35 MOZ Rank: 22

  • FDA approves first biosimilar for cancer treatment | FDA

    fda.gov

    https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-first-biosimilar-cancer-treatment

    WEBOn Sept. 14, 2017, the U.S. Food and Drug Administration approved Mvasi (bevacizumab-awwb, Amgen Inc.) as a biosimilar to Avastin (bevacizumab, Genentech Inc.). Mvasi is the first biosimilar...

    DA: 10 PA: 13 MOZ Rank: 71

  • Real-world usage of bevacizumab-bvzr biosimilar in US oncology …

    nih.gov

    https://pubmed.ncbi.nlm.nih.gov/35420744/

    WEBReal-world usage of bevacizumab-bvzr biosimilar in US oncology practice. Am J Manag Care. 2022 Apr;28 (4):160-166. doi: 10.37765/ajmc.2022.88831. Authors. Jingyan Yang 1 , John Mark Kelton , Jeffrey Thompson , Jose Maria Jimenez Alvir , Martine C Maculaitis , Ahmed Shelbaya. Affiliation. 1 Pfizer Inc, 235 E 42nd St, New York, NY 10017.

    DA: 41 PA: 83 MOZ Rank: 60